

A Concise Audit on the Screening Models for the Pharmacological Evaluation of Type-II Anti-Diabetic Medications

Deeksha Gupta*, Vishal Singh, Dakshina Gupta

Masters in Pharmacy(Pharmacology), Advance Institute of Biotechnology and Paramedical Sciences, Naramau, Kanpur, Uttar Pradesh, 209217.

Abstract: Background: The frequency of diabetes all over the globe has grown exotically over the recent past decades, and the vogue will continue for the anticipated future. The development of micro- and macro vascular complications is the dominant concern related to diabetes, whose contribution is highly proportional to the morbidity and mortality of the population with the disease. Advancement of the disease from pre-diabetic state to overt diabetes and the development of complexity transpire over many years. Reckoning of interventions crafted to delay or prevent disease amelioration or complexity in humans also takes years and desires impregnable resources.

Objective: None the less, for an animal model to have more convenience to the study of diabetes, the features of the animal model should portray the patho-physiology and natural history of diabetes or the model should flourish the complications of diabetes with an etiology congruent to that of the human condition. Use of the suitable animal model based on these homogeneities can provide much needed data on patho-physiological mechanisms operative in human type 2 diabetes mellitus.

Methods: A literature search was overseen by serving different keywords like "Type-II Diabetes Mellitus", " Anti-diabetic ", "*In-vitro* models" and "*In-vivo* models". The search was made to order by implementing convenient filters with a desire to fetch the best suited articles to meet the objective of this review article.


Result: There are different research and review papers based on the anti-diabetic screening models for the determination of anti-diabetic activity of new drug molecules.

Keywords: Type 2 diabetes mellitus; animal models; rodents; Insulin; Glucose

1. INTRODUCTION:

Type 2 diabetes mellitus is an interminable metabolic sickness that happen with glitch in emission and activity of insulin. An up hurled pace of basal hepatic glucose creation with hyper-insulinemia essentially come out with fasting hyperglycemia. Debilitated abrogation of hepatic glucose creation by insulin and devalued insulin-intervened glucose take-up by muscle conduce nearly to postprandial hyperglycemia after a supper [1]. Type 2 diabetes mellitus is a disease

highlighted by insulin hindrance and a propelled crumbling in pancreatic beta-cell work combined with blasting hyper-glycaemia. Flawed beta cell work happens somewhat past and can be track down in personages with fasting as well as post-prandial glucose levels been hindered generally named as "Pre-Diabetics" [5]. Notwithstanding hereditary inclination, up development of type 2 diabetes mellitus in advances in people in the skirt of mature age, corpulence, cardiovascular malady and a lacking physical work [2].




Fig(1): Possible risk factors leading to type2 diabetes mellitus

The patho-physiology of type 2 diabetes mellitus [Fig 3] is multifaceted and incorporates insulin discharge from pancreatic islet cells, insulin obstruction in fringe tissues, and insufficient concealment of glucagon creation. These procedures bring about lacking take-up, capacity, and removal of ingested glucose joined by raised hepatic creation of glucose and hyperglycemia. Loss of beta-cell mass in the pancreatic islets can advance to a clinically huge degree even, with the end goal that at the hour of conclusion of type 2 diabetes mellitus, a noteworthy number of cells may as of now be lost.


Numerous qualities have been recognized that are engaged with the advancement of type 2 diabetes mellitus, expanding our comprehension of the patho-physiology of type 2 diabetes mellitus and offering potential new treatment options. Newer

treatments for the administration of type 2 diabetes mellitus incorporate incretin-based agents, which act by focusing on huge numbers of the key patho-physiologic procedures in type 2 diabetes mellitus, including upgrading insulin discharge and restraining glucagon creation [8].

Proper test models are basic instruments for understanding the atomic premise, patho-beginning of the vascular and neural sores, activities of helpful operators and hereditary or ecological impacts that expansion the dangers of type 2 diabetes. Among the creature models accessible, those created in rodents have been read most completely for reasons, for example, short age time, acquired hyperglycaemia or potentially heftiness in specific strains and monetary contemplations [26].



Fig(2): Plasma glucose, insulin, and glucagon profiles in response to ingestion of a carbohydrate meal in normal individuals [35].



Fig(3): Type 2 diabetes mellitus Patho-Physiology [6].

Creature models permit investigation of the patho-physiology of sickness, and manage the cost of a way to contemplate the hidden biochemical and sub-atomic natural systems. While they can't be utilized altogether as a substitute for the investigation of human diabetes, they permit investigation of angles which can't morally be considered in the patient [4]. Diabetes examine in people is ruined by clear moral contemplations, as affectation of illness is carefully impermissible in human. Creature models of diabetes are along these lines incredibly helpful and invaluable in biomedical investigations as they offer promising new perceptiveness into human diabetes [2].

2. MATERIAL AND METHODS

A writing search was led on different database sources with the assistance of the mix of various watchwords: Against diabetic model, In-vitro, In-vivo models of type 2 diabetes mellitus movement. The pursuit was redone by applying the fitting channel in order to get the most pertinent articles to meet the goal of this survey. The different quantities of papers are available on the counter diabetic model for the recently orchestrated medications to decide their hostile to diabetic action.

3. TYPES OF MODELS FOR ANTI-DIABETIC ACTIVITY

After the debilitating writing review, we have seen that there is 'n' number of models present in which, some of them are not being used these days due to troubles in their methodology or on account of poor outcome, while there are some different models present which give great outcomes in a limited capacity to focus time. So essentially, these models are either utilized in the lab with the assistance of instruments and synthetic substances while in certain models, creature prerequisite is fundamental. Based on the philosophy, we isolate hostile to diabetic models concerning In-vitro or In-vivo. The creature isn't required for in-vitro models, while In-Vivo models, creatures are required for the improvement of hyperglycaemia and by the assistance of In-vivo model, we decide the movement of recently blended medication or atom. The motivation behind the survey is to talk about just the in-vivo models for screening of type 2 diabetes mellitus. In this way, these models are isolated into two gatherings which are as per the following.

3.1 In-vivo Models

The term in-vivo legitimately shows the assessment of medications in a living being, and assessment of the counter diabetic medications is inadequate without utilizing In-vivo model since diabetes is an infection which happens in the inward condition of the body and structures injuries in people. Type 2 diabetes mellitus instigated by the pharmacological, careful and by physiological control in the creature. Typically, a large portion of the trials are done in rodents [11]. The principle preferred position of these models is that we can decide the real enemy of diabetic action of medication planning, however it is a period taking procedure which is likewise an inconvenience of these models. Hostile to diabetic movement of medication planning likewise relies on the kind of models we select for the assurance of against diabetic property. In-vivo models are utilized for assessment of

against diabetic medications and these are as per the following.

3.1.1 Chemical Induced Diabetes Models

Type 2 diabetes Mellitus is instigated by means of a concoction specialist infused to the creature. The most widely recognized pharmacological model for diabetes in rodents and sheep is the organization of streptozotocin (STZ). It is for the most part utilized as a device for clarifying components which result from acceptance of the malady straightforwardly in the test creature [4].

Possible models that lay under the aforesaid method are:

- Neonatal Streptozotocin model of Type 2 diabetes mellitus
- Low dose STZ with high fat diet-fed rat model
- Nicotinamide -Streptozotocin (NAD-STZ) induced diabetic model
- Gold thioglucose obese diabetic mouse

3.1.1.1 Neonatal Streptozotocin model of Type 2 diabetes mellitus

Neonatal rodents STZ in portion of 80-100 mg/kg intra peritonally during childbirth or inside five days following birth is infused in the rodents. Serious pancreatic β cell demolition causes decline in insulin stores, increment in glucose levels. β cells of neonatal rodents incompletely recover because of high development thus the rodents become normo glycemic by 3 weeks old enough [20].

3.1.1.2 Low dose STZ with high fat diet-fed rat model

This model mirrors the normal history and metabolic attributes of human sort 2 diabetes [25]. High-vitality diet of 20% sucrose 10% grease and single infusion of STZ (30 mg/kg body weight) Incites type-2 diabetes following 4 a month and a half by adjustment of quality articulation in Sprague-Dawley rodents [9,10]. The high glucose-fat eating regimen is allowed for about a month and a half and afterward the low portion of streptozotocin is given intra peritonally [27].

3.1.1.3 Nicotinamide -Streptozotocin (NAD-STZ) induced diabetic model

Type 2 diabetes mellitus was prompted by a solitary intra peritoneal infusion of STZ (65mg/kg) and NAD (110mg/kg) [after 10 minutes] to rodents [28]. NAD is a cancer prevention agent which applies defensive impact on the cytotoxic activity of STZ by rummaging free radicals and makes just minor harm pancreatic beta cell mass delivering type-2 diabetes. Accordingly, this model is viewed as a worthwhile instrument for examination of insulinotropic specialists in the treatment of type2 diabetes mellitus [3].


3.1.1.4 Goldthioglucose obese diabetic mouse

Type 2 diabetes with heftiness is actuated in mice by goldthioglucose (GTG) (150-350 or 200 mg/kg, ip) injection. Mice step by step create stoutness, hyperinsulinaemia, hyperglycaemia, insulinresistance over a time of 16-20 wk after GTG infusion [29]. The GTG is shipped specifically to the cells of ventro average nerve center (VMH) and causes necrotic injuries, which consequently is answerable for the advancement of hyperphagia and heftiness. It likewise shows expanded body lipid and hepatic lipogenesis and triglyceride secretion, increased fat tissue lipogenesis and diminished glucose digestion in muscle, variations from the norm that are subjectively like hereditarily corpulent mice.

3.1.2 Hormone induced diabetes Models

Hyperglycemia and glucosuria in constrained took care of rodents treated with cortisone was seen in corticosteroid initiated diabetes [11]. In the guinea pigs and in the hares, trial corticoid diabetes could be gotten without constrained taking care of [12,13]. In the rodents, the adrenal cortex, animated by corticotrophin, has the ability to emit measures of steroids which incite steroid diabetes [14].

3.1.3 Genetic and Spontaneous models



Fig(4): Genetic Programming of development of Metabolic Syndrome [4]

Spontaneous models of type 2 diabetes mellitus are highly heterogeneous. At one end of the spectrum there is a mild hyperglycemia associated with obesity and hyperinsulinemia. At the other extreme, animal models of Type 2 diabetes mellitus can develop a severe form of diabetes mellitus with extensive β cell degeneration, occasionally resulting in ketosis models of type 2 diabetes mellitus are profoundly heterogeneous. Toward one side of the range there is a mellow hyperglycemia related with weight and hyperinsulinemia. At the other outrageous, creature models of Type 2 diabetes mellitus can build up an extreme type of diabetes mellitus with broad β cell degeneration, incidentally

bringing about ketosis and the necessity of exogenous insulin to continue life [15].

3.1.3.1 The fatty Zucker (Zucker diabetic fatty (ZDF)

The rodent has been esteemed as a model of corpulence, as the qualities of the model are portrayed as hyperglycemia, early hyperinsulinemia, fasting hyperglycemia, anomalous glucose resistance, hyperlipidemia, gentle hypertension. The ZDF rodent conveys the Lepfa or Ob-Rfa transformation, which is regularly alluded to as just fa [17].

3.1.3.2 The obese spontaneously hypertensive rat (SHORB),

The fat phenotype results from a transformation of leptin receptor assigned fak. SHORB is a valuable model to comprehend the connection of the different metabolic anomalies [18]. The heftiness transformations in the mouse ob (hefty) and db (diabetic) are change in the leptin basic quality (ob) and transformation in the leptin receptor quality (db). The large hyperglycemic disorder showed by these mice demonstrates different likenesses to type 2 diabetes mellitus. Insulin obstruction, wrong hyperglycemia, weakened glucose resistance just as expanded insulin discharge at long last prompting β cell fatigue are found in these models. Anyway age, sexual orientation, and upkeep conditions are accounted for to influence the phenotype of these mice.

3.1.3.3 The Spontaneously diabetic KK mice

They are accounted for to have moderate heftiness, polyphagia, polyurea, persitent glycosuria, glucose bigotry, moderate hyperglycemia, hyperlipidemia, insulin opposition of fringe tissues and hyperinsulinemia. The diabetic attributes of KK mice and the variation KKAY are returned to ordinary following 40 weeks old enough [19].

3.1.4 Dietary or nutrition induced type 2 diabetic models

A portion of the creature models exist in which diabetes is instigated neither by synthetic concoctions nor by hereditary imperfection. Sand rodent, Tuco-Tuco and Spiked mouse are significant models of healthfully actuated corpulence and type 2 diabetes [21].

3.1.4.1 Sand rat (Psammomys obesus)

It is a model of healthfully actuated Sort 2 diabetes mellitus. Psammomys is inclined to creating hyperinsulinemia, hyperglycemia and weight when moved to a high-vitality diet, likewise essential insulin obstruction is an animal varieties portrayal of Psammomys [22,23]. In any case, the possibility to become diabetic declines with age. In Psammomys of ages 1 a year, kept up on a low-vitality diet from weaning and moved at various ages to a high-vitality diet [16], the affectability to the advancement of diabetes mellitus increments from weaning to a pinnacle of around 5 months old enough and diminishes from there on.

3.1.5 Surgical type 2 diabetic models

This strategy comprises of complete or halfway pancreatectomy in creatures utilized for the enlistment of type 1 or type 2 diabetes, separately. Historically, the diabetic pooch model found by Oskar Minkowski through careful complete pancreatectomy has been viewed as the main creature model of diabetes and is once in a while now utilized for the examination. Be that as it may, halfway pancreatectomy and additionally mix strategies on creatures especially non rodents are on occasion used in the diabetes examination for some particular investigations as portrayed underneath.

3.1.5.1 VMH dietary obese diabetic rat model

It has been created by trial careful control of hereditarily typical creatures without the decrease in pancreatic beta cell mass taking after sort 2 diabetes by joining reciprocal electrolyte sore of VMH and taking care of high fat and high sucrose consumes less calories named as VMH dietary fat rodents [24]. It is described by stamped heftiness, hyper-insulinaemia, hyper-triglyceridaemia, insulin obstruction, weakened glucose resilience, moderate to severe fasting hyperglycaemia and imperfect guideline of insulin secretory reaction regardless of very high insulin secretory limit. It is fascinating that huge hyperphagia is seen in spite of expanded leptin levels (leptin obstruction) in these VMH sore rodents.

3.1.5.2 Non obese partial pancreatectomized diabetic animals

Incomplete pancreatectomy in creatures proceeded as 70 or 90 percent (typically 90%) analyzation of pancreas has been accounted for in different creature species for the most part in hounds, pigs, bunny and furthermore rodents [30,31,32]. It doesn't cause extreme type of diabetes and is portrayed by moderate hyperglycaemia with neither decrease in body weight nor decrease in plasma insulin levels. The 90 percent in part pancreatectomized rodents likewise demonstrate imperfection or particular impedance to glucose invigorated insulin discharge however stay unblemished to other insulin secretogogues like neonatal STZ rodents. This finding from these fractional pancreatectomized creatures bolsters the thought that just decrease in pancreatic beta cell mass itself may not be liable for the glucose narrow mindedness as observed in neonatal STZ rodents [33]. These fractional pancreatectomized creatures are accounted for to create hyperglycaemia and insulin opposition. Improvement of hyperglycaemia and insulin resistance is seen by organization of insulinor phlorizin, an inhibitor of renal glucose re assimilation [34].

3.1.6 Oral glucose loading animal model

This technique is frequently alluded to as physiological enlistment of diabetes mellitus on the grounds that the blood glucose level of the creature is fleetingly expanded with no harm to the pancreas. In the clinical setting, it is known as Glucose resilience testing (GTT): a standard system regularly utilized for the finding of marginal diabetic patients. In this strategy, the creatures are fasted for the time being, at that point oral glucose load (1-2.5 g/kg body weight) is given and blood glucose level is observed over some stretch of time. Typically bunnies or male rodents are utilized. Etuk and

Mohammed (Unpublished) utilized this strategy to instigate hyperglycaemia in wistar rodents. The strategy was found to create a generally fluctuating degree of hyperglycaemia when contrast with alloxan enlistment technique [46].

4. END-POINTS TO STUDY ANIMAL MODELS OF DIABETES

When testing treatments in creature models of diabetes, the most widely recognized end-purpose of estimation is blood glucose focuses. It ought to be called attention to that various species will in general have diverse blood glucose focuses than people, and along these lines, definitions for diabetes in people ought not really be applied to creatures. Location of glucose in the pee can likewise be estimated as an indication of diabetes. Be that as it may, in a mind boggling ailment, for example, diabetes, opposite end-focuses ought to be researched. Different endpoints will rely upon the putative component of the medication and the model being utilized. The time course of the malady ought to likewise be painstakingly viewed as when considering end-purposes of an examination. A few models of type 2 diabetes show beta cell development and hyper insulinaemia before resulting beta cell disappointment, and the phase of sickness may influence the parameters that are being estimated. Notwithstanding, it ought to be noticed that in models of type 2 diabetes, the system of the medication bringing down blood glucose levels may incorporate weight reduction [36]. Glucose resilience tests are frequently used to research beta cell work. This can permit impeded glucose resistance to be distinguished, which is for the most part viewed as a pre-diabetic state. This is frequently done after a short-term quick, in spite of the fact that it ought to be noticed that it has been proposed that such a drawn out quick might be unseemly in mice as it prompts a metabolic pressure and improves insulin activity [37], and subsequently, a 6 h quick might be ideal. There are no away from of impeded glucose resistance for rodents, yet in ordinary nondiabetic mice, an IPGTT arrives at a top at 15–30 min; and by 120 min, the blood glucose ought to be near the pattern esteem [38]. Serum insulin or c-peptide levels can be estimated to show beta cell work, albeit high insulin levels can in a roundabout way demonstrate insulin obstruction. An insulin resilience test can be completed as a surmised proportion of insulin obstruction, or a progressively rich hyperinsulinaemic–euglycaemic brace can be done [39]. It ought to be noticed that proxy proportions of insulin affectability, for example, the homeostasis model file of insulin opposition (HOMA-IR) can be utilized in rodents, despite the fact that species explicit changes may should be made [40]. It ought to likewise be noticed that in people, type 2 diabetes will in general present sometime down the road, and in this manner, the utilization of more established mice when contemplating this condition ought to be thought of.

5. SELECTION OF APPROPRIATE MODEL FOR TYPE 2 DIABETES MELLITUS

An assortment of creature models of type 2 diabetes are portrayed over, each with their own attributes. There are a few unique purposes that these models of diabetes could be utilized for including pharmacological testing, investigations of hereditary qualities and understanding infection systems. The decision of model will rely upon the motivation behind the investigation. For instance, on account of

pharmacological testing, the putative component of the medication being tried will be instrumental in picking a proper creature model [41]. In type 2 diabetes, it is essential to consider the systems basic the hyperglycaemia and whether this is applicable to your examination. These systems can incorporate insulin opposition or potentially beta cell disappointment. To be sure, to decide if a medication intercession can improve manifestations in some random model may rely upon whether beta cells have fizzled. Creature models of type 2 diabetes can be partitioned into those that are stout and those that are nonobese. Most of type 2 diabetes models are stout, by either hereditary or dietary methods. Be that as it may, this normally accompanies an assortment of related pathologies, for example, dyslipidaemia and arteriosclerosis. In spite of the fact that these comorbidities are basic in certain people with type 2 diabetes, it just speaks to a bit of the diabetic populace. Likewise, it ought to be noticed that not every single creature model of diabetes and strains create diabetic inconveniences [42], so care ought to be taken in picking a suitable model if the end-point of the examination is to research diabetic difficulties, for example, nephropathy or neuropathy [43,44,45].

6. CONCLUSION

A large number of the creature models depicted obviously share comparative trademark highlights of type 2 diabetes and have permitted experimentation that would be unimaginable in people. None of the realized single species is actually proportionate to human diabetes, yet each model go about as basic apparatus for exploring hereditary, endocrine, metabolic, morphologic changes and hidden aetiopathogenic instruments that could likewise work during the advancement of type 2 diabetes in people. Subsequently, care must be taken in understanding and extrapolation of the outcomes acquired from these creature models to people. In the screening project of against diabetic mixes, it is especially critical to take note of that some creature models are more qualified to screen specific class of hostile to diabetic mixes. Since beginning restorative science crusades and screening, for the most part require the testing of numerous mixes in the mechanical research condition, utilization of littler creature models, for example, mice, will diminish the cost of delivering test materials while some propelled adequacy contemplates or toxicological assessments which require obtrusive methodology and huge blood and tissue tests, might be encouraged by utilizing creatures with huge body size, for example, rodent or other non rodents. Further, the choice of specific creature model is especially relying upon the specialist's decision whether to utilize innate or outbred, accessibility of specific strain, point of logical technique, kind of medication being looked for, institutional money related and office assets in the sort 2 diabetes inquire about and pharmaceutical medication disclosure and advancement program. In spite of the fact that there are a few constraints like cost, down to earth troubles, extraordinary consideration and moral contemplations related with the utilization of enormous/non rat creature species (pigs, hounds and non human primates), the definite examinations in these diabetic creature species are direly required for better comprehension of the sickness components in much intently comparative human circumstance just as for finding more up to date targets and medications for the treatment of type 2 diabetes and its entanglements.

7. REFERENCES:

1. Ralph A. DeFronzo et al, Pharmacologic Therapy for Type 2 Diabetes Mellitus 1999 American College of Physicians–American Society of Internal Medicine, 17 August 1999 • Annals of Internal Medicine • Volume 131 • Number 4
2. Animal models in type 2 diabetes research: An overview by K. Srinivasan & P. Ramarao Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education & Research (NIPER), Mohali, India
3. Pellegrino M, Christopher B, Michelle M, et al. Diabetes 1998; 47: 224-230
4. Ingle DJ, Li CH, Evans HM (1946) The effect of adrenocorticotrophic hormone on the urinary excretion of sodium, chloride, potassium, nitrogen and glucose in normal rats. Endocrinology 39:32–39
5. L H Bösenberg & D G van Zyl (2008) The mechanism of action of oral antidiabetic drugs: A review of recent literature, Journal of Endocrinology, Metabolism and Diabetes of South Africa, 13:3, 80-88, DOI: 10.1080/22201009.2008.10872177
6. DeFronzo RA. Diabetes. 2009 Apr;58(4):773-95 Inzucchi SE, Sherwin RS in: Cecil Medicine 2011 Inzucchi SE, Sherwin RS in: Cecil Medicine 2011
8. Craig W. Spellman, DO, PhD, Spellman • Pathophysiology of Type 2 Diabetes: Targeting Islet Cell Dysfunction JAOA • Supplement 2 • Vol 110 • No 3 • March 2010 • S7
9. Hui JW, Yuan XJ, Shen W, et al. Asia Pacific Journal of Clinical Nutrition 2007; 16 (1, suppl): 412-417.
10. Srinivasan K, Viswanad B, Lydia Asrat, et al. Pharmacological Research 2005; 52: 313–320.
11. Ingle DJ (1941) The production of glycosuria in the normal rat by means of 17-hydroxy-11-dehydrocorticosterone. Endocrinology 29:649–652
12. Hausberger FX, Ramsay AJ (1953) Steroid diabetes in guinea pigs. Effect of cortisone administration on blood- and urinary glucose, nitrogen excretion, fat deposition, and the islets of Langerhans. Endocrinology 53:423–435
13. Abelove WA, Paschkis KE (1954) Comparison of the diabetogenic action of cortisone and growth hormone in different species. Endocrinology 55:637–654
14. Ingle DJ, Li CH, Evans HM (1946) The effect of adrenocorticotrophic hormone on the urinary excretion of sodium, chloride, potassium, nitrogen and glucose in normal rats. Endocrinology 39:32–39
15. Pickup JC and Williams G, editors. Textbook of diabetes. 3rd Ed, USA: Blackwell Science Ltd 2003.

16. Ziv E, Shafir E, Kalman R, Galer S, Bar-On H. Changing patterns of prevalence of insulin resistance in Psammomys obesus, a model of nutritionally-induced Type 2 diabetes. *Metabolism* 1999;48:1549-54. Back to cited text no. 3 [PUBMED]
17. Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effects of dietary fat on the development of non-insulin dependant diabetes mellitus in obese Zucker diabetic fatty male and female rat. *Atherosclerosis* 2000;48:231-41
18. Ishizuka T, Ernsberger P, Liu S, Bedol D, Lehman TM, Koletsky RJ. Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fak) in obese spontaneously hypertensive Koletsky rat (SHORB). *J Nutr* 1998;128:2299-306.
19. Suto JS, Matsuura S, Imamura K. Genetic analysis of non-insulin dependent diabetes mellitus in KK and KK-Ay mice. *Eur J Endocrinol* 1998;139:654-61.
20. Okamoto H. Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin dependant diabetes. *Mol Cell Biochem* 1981;37:43-61.
21. Shafir E. Diabetes in animals: Contribution to the understanding of diabetes by study of its etiopathology in animal models. In: Porte D, Sherwin RS, Baron A, editors. *Diabetes mellitus*. New York: McGraw-Hill; 2003p. 231-55
22. Shafir E, Ziv E, Mosthaf L. Nutritionally induced insulin resistance and receptor defect leading to beta cell failure in animal models. *Ann NY Acad Sci* 1999;892 : 223-46
23. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) strain. *Diabetes* 1992; 41 : 1422-8
24. Axen KV, Li X, Fung K, Sclafani A. The VMH-dietary obese rat: a new model of non-insulin-dependent diabetes mellitus. *Am J Physiol* 1994; 266 : R921-8
25. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening: K. Srinivasan B. Viswanad, Lydia Asrat, C.L. Kaul P. Ramarao Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, Phase X, S.A.S. Nagar, Mohali 160 062, Punjab, India
26. Development and application of rodent models for type 2 diabetes Desu Chen Ming-Wei Wang
27. Anti-diabetic effects of shubat in type 2 diabetic rats induced by combination of high-glucose-fat diet and low-dose streptozotocin Tabusi Manaer, Lan Yu, Yi Zhang, Xue-Jun Xiao, Xin-Hu, Nabia Department of Pharmacology, Xinjiang Medical University, Urumqi 830011, China Xinjiang Uyghur Autonomous Region Institute for Food and Drug Control, Urumqi 830004,.
28. International Journal of Advances in Pharmaceutical Sciences 1 (2010) 75-85 Studies on the anti-diabetic and hypolipidemic potentials of mangiferin (Xanthone Glucoside) in streptozotocin-induced Type 1 and Type 2 diabetic model rats by B Dineshkumar, Analava Mitra1, M Manjunatha.
29. Le Marchand Brustel Y, Jeanrenaud B, Freychet P. Insulin binding and effects in isolated soleus muscle of lean and obese mice. *Am J Physiol* 1978; 234: E348-58.
30. McNeil JH. Experimental models of diabetes. Florida, USA: CRC Press LLC; 1999.
31. Ibanez-Camacho R, Meckes-Lozaya M, Mellado-Campos V. The hypoglycemic effect of *Opuntia streptocarpa* studied in different animal experimental models. *J Ethnopharmacol* 1983; 7 : 175-81.
32. Sasaki S, Nio Y, Hirahara N, Sato Y, Inoue Y, Iguchi C, et al. Intraperitoneally implanted artificial pancreas with transkaryotic beta-cells on micro carrier beads in a diffusion chamber improves hyperglycemia after 90% pancreatectomy in rats. *In Vivo* 2000; 14 : 535-41
33. Portha B, Giroix M-H, Serradas P, Morin L, Tormo M-A, Bailbe D. Cellular basis for glucose refractoriness of pancreatic B-cells in non insulin dependent diabetes. In: Flatt PR, Lenzen S, editors. *Insulin secretion and pancreatic B cell research*. UK: Smith-Gordon, 1994 p.461-72.
34. Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. *J Clin Invest* 1983; 71 : 1544-53
35. Unger RH. *N Engl J Med*. 1971;285(8):443-449. Copyright 1971 Massachusetts Medical Society.
36. Knudsen LB (2010). Liraglutide: the therapeutic promise from animal models. *Int J Clin Pract Suppl*. 64: 4-11
37. McGuinness OP, Ayala JE, Laughlin MR, Wasserman DH (2009). NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. *Am J Physiol Endocrinol Metab* 297: E849-E855.
38. Leiter EH (2009). Selecting the 'right' mouse model for metabolic syndrome and type 2 diabetes research. *Methods Mol Biol* 560: 1-17.
39. Declercq J, Kumar A, Van Diepen JA, Vroegrijk IOCM, Gysemans C, Di Pietro C et al. (2010). Increased β -cell mass by islet transplantation and PLAG1 overexpression causes hyperinsulinemic normoglycemia and hepatic insulin resistance in mice. *Diabetes* 59: 1957-1965.
40. Mather K (2009). Surrogate measures of insulin resistance: of rats, mice, and men. *Am J Physiol Endocrinol Metab* 296: E398-E399.
41. Review on Use of Animal Models in Diabetes Research by Aileen JF King, Diabetes Research Group, King's College London, London, UK DOI:10.1111/j.1476-5381.2012.01911.x

42. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB et al . (2009a). Mouse models of diabetic nephropathy. *J Am Soc Nephrol* 20: 2503–2512.
43. Breyer MD, Bottinger E, Brosius FC, Coffman TM, Fogo A, Harris RC et al . (2005). Diabetic nephropathy: of mice and men. *Adv Chronic Kidney Dis* 12: 128–145.
44. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su OS, Lentz SI et al . (2007). Mouse models of diabetic neuropathy. *Neurobiol Dis* 28: 276–285.
45. Brosius FC III, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB et al . (2009b). Mouse models of diabetic nephropathy. *J Am Soc Nephrol* 20: 2503–2512.
46. Animals models for studying diabetes mellitus Etuk, E.U
Department of Pharmacology, College of Health Sciences,
Usmanu Danfodiyo University, Sokoto, Nigera

